Table of Contents Author Guidelines Submit a Manuscript
Pain Research and Management
Volume 2017, Article ID 5402915, 11 pages
https://doi.org/10.1155/2017/5402915
Research Article

Perceptions of Community-Dwelling Patients and Their Physicians on OxyContin® Discontinuation and the Impact on Chronic Pain Management

School of Pharmacy, University of Waterloo, Waterloo, ON, Canada

Correspondence should be addressed to Feng Chang; ac.oolretawu@gnahc.gnef

Received 9 February 2016; Revised 2 December 2016; Accepted 9 January 2017; Published 30 January 2017

Academic Editor: Alison Twycross

Copyright © 2017 Feng Chang and Sara Ibrahim. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. Pan, Z. Zhang, Y. Zhang et al., “Efficacy and tolerability of oxycodone hydrochloride controlled-release tablets in moderate to severe cancer pain,” Clinical Drug Investigation, vol. 27, no. 4, pp. 259–267, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. M. H. Levy, “Pharmacologic treatment of cancer pain,” The New England Journal of Medicine, vol. 335, no. 15, pp. 1124–1132, 1996. View at Publisher · View at Google Scholar
  3. Purdue Pharma, OxyContin Product Monograph, http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020553s060lbl.pdf.
  4. Canadian Center on Substance Abuse, “OxyContin FACTSHEET,” http://www.ccsa.ca/Resource Library/ccsa-003642-2006.pdf.
  5. I. A. Dhalla, M. M. Mamdani, M. L. A. Sivilotti, A. Kopp, O. Qureshi, and D. N. Juurlink, “Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone,” CMAJ, vol. 181, no. 12, pp. 891–896, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. Canadian Agency for Drugs and Technologies in Health, The Use of OxyContin and OxyNeo in Adults: A Review of the Evidence on Safety, https://www.cadth.ca/sites/default/files/pdf/htis/may-2013/RC0301-000 OxyNEO.pdf.
  7. T. J. Cicero, J. A. Inciardi, and A. Muñoz, “Trends in abuse of OxyContin and other opioid analgesics in the United States: 2002–2004,” Journal of Pain, vol. 6, no. 10, pp. 662–672, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. E. Haydon, J. Rehm, B. Fischer, N. Monga, and E. Adlaf, “Prescription drug abuse in Canada and the diversion of prescription drugs into the illicit drug market,” Canadian Journal of Public Health, vol. 96, no. 6, pp. 459–461, 2005. View at Google Scholar · View at Scopus
  9. D. E. Joranson and A. M. Gilson, “Drug crime is a source of abused pain medications in the United States,” Journal of Pain and Symptom Management, vol. 30, no. 4, pp. 299–301, 2005. View at Publisher · View at Google Scholar · View at Scopus
  10. K. D. Shield, A. Ialomiteanu, B. Fischer, R. E. Mann, and J. Rehm, “Non-medical use of prescription opioids among Ontario adults: data from the 2008/2009 CAMH Monitor,” Canadian Journal of Public Health, vol. 102, no. 5, pp. 330–335, 2011. View at Google Scholar · View at Scopus
  11. E. C. Ong, “Controlled-release oxycodone in the treatment of neuropathic pain of nonmalignant and malignant causes,” Oncology, vol. 74, supplement 1, pp. 72–75, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. S. S. Jayawant and R. Balkrishnan, “The controversy surrounding OxyContin abuse: issues and solutions,” Therapeutics and Clinical Risk Management, vol. 1, no. 2, pp. 77–82, 2005. View at Publisher · View at Google Scholar
  13. A. Van Zee, “The promotion and marketing of oxycontin: commercial triumph, public health tragedy,” American Journal of Public Health, vol. 99, no. 2, pp. 221–227, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. Ontario Ministry of Health and Long Term Care, “Ontario’s narcotics strategy: change in funding status of oxycodone controlled release tablet—(Discontinuation of Oxycontin and introduction of OxyNeo),” http://www.health.gov.on.ca/en/public/programs/drugs/ons/oxy_faq.aspx.
  15. International Narcotics Control Board. Report of the International Narcotics Control Board on the Availability of Internationally Controlled Drugs: Ensuring Adequate Access for Medical and Scientific Purposes, 2010, https://www.incb.org/documents/Publications/AnnualReports/AR2010/Supplement-AR10_availability_English.pdf.
  16. Industry Canada, Pharmaceutical industry profile, 2010, https://www.ic.gc.ca/eic/site/lsg-pdsv.nsf/eng/h_hn01703.html.
  17. T. Gomes, M. M. Mamdani, I. A. Dhalla, S. Cornish, J. M. Paterson, and D. N. Juurlink, “The burden of premature opioid-related mortality,” Addiction, vol. 109, no. 9, pp. 1482–1488, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Cupp, New Oxycodone Formulation: OxyNeo. PL Detail-Document #280121 2012.
  19. Ontario Ministry of Health and Long-Term Care, “OxyNEO-Changes to OBD Formulary. Toronto,” 2012, http://www.cpso.on.ca/uploadedfiles/policies/positions/oxyneo.pdf.
  20. S. Lunn, Generic OxyContin approved for 6 drugmakers—Politics —CBC News. CBC News, 2012, http://www.cbc.ca/news/politics/generic-oxycontin-approved-for-6-drugmakers-1.1242929.
  21. R. Chou, J. A. Turner, E. B. Devine et al., “The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a national institutes of health pathways to prevention workshop,” Annals of Internal Medicine, vol. 162, no. 4, pp. 276–286, 2015. View at Publisher · View at Google Scholar · View at Scopus
  22. M. L. Reitsma, J. E. Tranmer, D. M. Buchanan, and E. G. VanDenKerkhof, “The epidemiology of chronic pain in Canadian men and women between 1994 and 2007: results from the longitudinal component of the National Population Health Survey,” Pain Research and Management, vol. 17, no. 3, pp. 166–172, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. D. E. Moulin, A. J. Clark, M. Speechley, and P. K. Morley-Forster, “Chronic pain in Canada—prevalence, treatment, impact and the role of opioid analgesia,” Pain Research and Management, vol. 7, no. 4, pp. 179–184, 2002. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Boulanger, A. J. Clark, P. Squire, E. Cui, and G. L. A. Horbay, “Chronic pain in Canada: have we improved our management of chronic noncancer pain?” Pain Research and Management, vol. 12, no. 1, pp. 39–47, 2007. View at Publisher · View at Google Scholar · View at Scopus
  25. C. J. Evans, E. Trudeau, P. Mertzanis et al., “Development and validation of the pain treatment satisfaction scale (PTSS): a patient satisfaction questionnaire for use in patients with chronic or acute pain,” Pain, vol. 112, no. 3, pp. 254–266, 2004. View at Publisher · View at Google Scholar · View at Scopus
  26. S. Keller, C. M. Bann, S. L. Dodd, J. Schein, T. R. Mendoza, and C. S. Cleeland, “Validity of the brief pain inventory for use in documenting the outcomes of patients with noncancer pain,” Clinical Journal of Pain, vol. 20, no. 5, pp. 309–318, 2004. View at Publisher · View at Google Scholar · View at Scopus
  27. G. Tan, M. P. Jensen, J. I. Thornby, and B. F. Shanti, “Validation of the brief pain inventory for chronic nonmalignant pain,” Journal of Pain, vol. 5, no. 2, pp. 133–137, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. T. J. Cicero, M. S. Ellis, and H. L. Surratt, “Effect of abuse-deterrent formulation of OxyContin,” The New England Journal of Medicine, vol. 367, no. 2, pp. 187–189, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. T. A. Cassidy, P. Dasmahapatra, R. A. Black, M. S. Wieman, and S. F. Butler, “Changes in prevalence of prescription opioid abuse after introduction of an abuse-deterrent opioid formulation,” Pain Medicine, vol. 15, no. 3, pp. 440–451, 2014. View at Publisher · View at Google Scholar · View at Scopus
  30. S. G. Mars, P. Bourgois, G. Karandinos, F. Montero, and D. Ciccarone, “‘Every ‘Never’ I ever said came true’: transitions from opioid pills to heroin injecting,” International Journal of Drug Policy, vol. 25, no. 2, pp. 257–266, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. J. Benbassat, D. Pilpel, and M. Tidhar, “Patients' preferences for participation in clinical decision making: a review of published surveys,” Behavioral Medicine, vol. 24, no. 2, pp. 81–88, 1998. View at Publisher · View at Google Scholar · View at Scopus
  32. L. A. Anderson and M. A. Zimmerman, “Patient and physician perceptions of their relationship and patient satisfaction: a study of chronic disease management,” Patient Education and Counseling, vol. 20, no. 1, pp. 27–36, 1993. View at Publisher · View at Google Scholar · View at Scopus
  33. L. M. L. Ong, J. C. J. M. De Haes, A. M. Hoos, and F. B. Lammes, “Doctor-patient communication: a review of the literature,” Social Science and Medicine, vol. 40, no. 7, pp. 903–918, 1995. View at Publisher · View at Google Scholar · View at Scopus
  34. P. L. Stillman, D. R. Brown, D. L. Redfield, and D. L. Sabers, “Construct validation of the arizona clinical interview rating scale,” Educational and Psychological Measurement, vol. 37, no. 4, pp. 1031–1038, 1977. View at Publisher · View at Google Scholar · View at Scopus
  35. I. K. Zola, “Pathways to the doctor—from person to patient,” Social Science and Medicine, vol. 7, no. 9, pp. 677–689, 1973. View at Publisher · View at Google Scholar · View at Scopus
  36. L. M. E. Frantsve and R. D. Kerns, “Patient-provider interactions in the management of chronic pain: current findings within the context of shared medical decision making,” Pain Medicine, vol. 8, no. 1, pp. 25–35, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. F. S. Smyth, “The place of the humanities and social sciences in the education of physicians,” Journal of Medical Education, vol. 37, no. 5, pp. 495–499, 1962. View at Google Scholar · View at Scopus
  38. M. B. Wanzer, M. Booth-Butterfield, and K. Gruber, “Perceptions of health care providers' communication: relationships between patient-centered communication and satisfaction,” Health Communication, vol. 16, no. 3, pp. 363–383, 2004. View at Publisher · View at Google Scholar · View at Scopus
  39. J. H. Robinson, L. C. Callister, J. A. Berry, and K. A. Dearing, “Patient-centered care and adherence: definitions and applications to improve outcomes,” Journal of the American Academy of Nurse Practitioners, vol. 20, no. 12, pp. 600–607, 2008. View at Publisher · View at Google Scholar · View at Scopus
  40. S. E. Ward, N. Goldberg, V. Miller-McCauley et al., “Patient-related barriers to management of cancer pain,” Pain, vol. 52, no. 3, pp. 319–324, 1993. View at Publisher · View at Google Scholar · View at Scopus
  41. M. Kahan, L. Wilson, E. F. Wenghofer et al., “Pharmacists' experiences with dispensing opioids: provincial survey,” Canadian Family Physician, vol. 57, no. 11, pp. e448–e454, 2011. View at Google Scholar · View at Scopus
  42. H. M. Gugelmann and J. Perrone, “Can prescription drug monitoring programs help limit opioid abuse?” The Journal of the American Medical Association, vol. 306, no. 20, pp. 2258–2259, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. L. Manchikanti, R. Manchukonda, V. Pampati et al., “Does random urine drug testing reduce illicit drug use in chronic pain patients receiving opioids?” Pain Physician, vol. 9, no. 2, pp. 123–129, 2006. View at Google Scholar · View at Scopus
  44. P. J. Christo, L. Manchikanti, X. Ruan et al., “Urine drug testing in chronic pain,” Pain Physician, vol. 14, no. 2, pp. 123–143, 2011. View at Google Scholar · View at Scopus
  45. D. L. Gourlay, H. A. Heit, and A. Almahrezi, “Universal precautions in pain medicine: a rational approach to the treatment of chronic pain,” Pain Medicine, vol. 6, no. 2, pp. 107–112, 2005. View at Publisher · View at Google Scholar · View at Scopus
  46. Health Canada, “Health Canada's Action on Opioid Misuse,” 2016 http://healthycanadians.gc.ca/healthy-living-vie-saine/substance-abuse-toxicomanie/misuse-plan-abus-index-eng.php?_ga=1.50983082.289117723.1457710708.
  47. Ontario Ministry of Health and Long-term Care. Ontario Taking Action to Prevent Opioid Abuse, 2016, https://news.ontario.ca/mohltc/en/2016/10/ontario-taking-action-to-prevent-opioid-abuse.html.
  48. Government of Canada, “Joint Statement of Action to Address the Opioid Crisis,” 2016 http://www.healthycanadians.gc.ca/healthy-living-vie-saine/substance-abuse-toxicomanie/opioids-opioides/conference-cadre/statement-declaration-eng.php.
  49. E. F. Wenghofer, L. Wilson, M. Kahan et al., “Survey of Ontario primary care physicians' experiences with opioid prescribing,” Canadian Family Physician, vol. 57, no. 3, pp. 324–332, 2011. View at Google Scholar · View at Scopus
  50. A. D. Furlan, R. Reardon, and C. Weppler, “Opioids for chronic noncancer pain: a new Canadian practice guideline,” Canadian Medical Association Journal, vol. 182, no. 9, pp. 923–930, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. M. N. Scanlon and U. Chugh, “Exploring physician's comfort level with opioids for chronic noncancer pain,” Pain Research and Management, vol. 9, no. 4, pp. 195–201, 2004. View at Publisher · View at Google Scholar · View at Scopus
  52. T. W. Victor, N. A. Alvarez, and E. Gould, “Opioid prescribing practices in chronic pain management: guidelines do not sufficiently influence clinical practice,” Journal of Pain, vol. 10, no. 10, pp. 1051–1057, 2009. View at Publisher · View at Google Scholar · View at Scopus
  53. J. D. Darer, W. Hwang, H. H. Pham, E. B. Bass, and G. Anderson, “More training needed in chronic care: a survey of U.S. physicians,” Academic Medicine, vol. 79, no. 6, pp. 541–548, 2004. View at Publisher · View at Google Scholar · View at Scopus
  54. D. S. Bennett and D. B. Carr, “Opiophobia as a barrier to the treatment of pain,” Journal of Pain and Palliative Care Pharmacotherapy, vol. 16, no. 1, pp. 105–109, 2002. View at Publisher · View at Google Scholar · View at Scopus